Surgery for Pancreatic Cancer With Oligo-Metastasis

Surgery/Destruction for Stage IV Pancreatic Cancer With Oligo-Metastatic Disease

Pancreatic cancer is increasing in incidence and will be the second leading cause of cancer-related deaths in 2030 in the West. Only 10 to 15% of patients are eligible for curative resection with long-term survival rarely exceeding 20% at 5 years. The management of metastatic or recurrent diseases can not, unfortunately, be recommended to date because of limited data available (INCA 2019).

However, recent, low-strength publications have reported encouraging results on the long-term survival of stage IV or recurrent patients.

The aim of the present retrospective cohort study is to analyze results of surgery/destruction of metastatic synchronous or metachronous disease or local recurrence in patients with stage IV pancreatic cancer

Inclusion criteria:

- Patients who had resection or destruction of one or more synchronous or metachronous metastases or local recurrence of pancreatic adenocarcinoma

Details:

• synchronous lesions, metachrones can be included
• all distant lesions (hepatic, pulmonary) can be included
• documented lymph node involvement after analysis of the specimen (hepatic hilum, mesenteric root, retroperitoneal or inter-aortic-cellar) can be included
• patients with local recurrence who underwent surgical treatment

Exclusion Criteria:

- Patient who reject the study protocol